Page last updated: 2024-11-13

3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester: a breast cancer resistance protein (BCRP) inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID69534441
SCHEMBL ID5696166
MeSH IDM0536777

Synonyms (4)

Synonym
3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester
FT-0670686
SCHEMBL5696166
HMS3740M21

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The design, synthesis, in vitro inhibitory potency, and pharmacokinetic (PK) profiles of Ko143 analogs are described."( Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
Chmielecki, J; Chuang, BC; Guan, MY; Li, Y; Liao, M; Plesescu, M; Prakash, SR; Woo, J; Xia, CQ; Yang, JJ, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" Such clarification may lead to the development of strategies to overcome efflux and enhance its bioavailability at target site."( Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance.
Kwatra, D; Mitra, AK; Pal, D; Vadlapatla, RK; Vadlapudi, AD, 2010
)
0.36
"It was recently proposed that the improved oral bioavailability of genistein aglycone and conjugates in Bcrp1(-/-) mice is mainly due to increased intestinal absorption of aglycone and subsequent elevated exposure to conjugation enzymes."( Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein.
Gao, S; Hu, M; Jiang, W; Yang, Z; Yin, T; Zhu, W, 2012
)
0.38
"It may be concluded that BCRP plays an important role in the intestinal efflux of MED-5 and limits the bioavailability after oral administration of MED-15."( Evaluation of intestinal absorption of amtolmetin guacyl in rats: breast cancer resistant protein as a primary barrier of oral bioavailability.
Li, X; Liu, D; Rong, Z; Xiang, D; Xu, Y; Zhang, C, 2013
)
0.39
" This experimental system is useful for clarifying the cause of low bioavailability of various drugs."( In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats.
Hashimoto, T; Konno, Y; Matsuda, Y; Nagai, M; Satsukawa, M; Taguchi, T; Yamashita, S, 2013
)
0.39
"Bazedoxifene, a novel selective estrogen receptor modulator, has complex pharmacokinetics with rapid absorption, high metabolic clearance, low oral bioavailability (6."( Efflux and uptake transporters involved in the disposition of bazedoxifene.
Berginc, K; Kristl, A; LuĊĦin, TT; Mrhar, A; Stieger, B; Trontelj, J, 2016
)
0.43
"54L/h/kg] and higher bioavailability [123%])."( Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles.
Chmielecki, J; Chuang, BC; Guan, MY; Li, Y; Liao, M; Plesescu, M; Prakash, SR; Woo, J; Xia, CQ; Yang, JJ, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (67)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (4.48)29.6817
2010's55 (82.09)24.3611
2020's9 (13.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.40 (24.57)
Research Supply Index4.25 (2.92)
Research Growth Index5.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other68 (98.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]